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Abstract 
We report a case of a 63-year-old man hospitalized for a polymorphous generalized eruption 
consisting of maculopapules with peripheral scaling, vesicopustules, and ulceronecrotic and 
crusted lesions measuring 5–20 mm, localized on his trunk and extremities, particularly 
exuberant in the flexural area. Histopathology showed necrotic keratinocytes with 
exocytosis of red blood cells and lymphocytes and a dermal perivascular and periadnexal 
inflammatory infiltrate, composed of CD8+/CD4–/CD30– T cells, indicating the clinical 
diagnosis of pityriasis lichenoides et varioliformis acuta. He was treated with erythromycin 
and methylprednisolone reduced gradually over 5 months, with a slow but complete 
response; the patient was without lesions after 2 years of follow-up. The authors want to 
remind of this rare entity which may present difficulties in diagnosis and therapy. 
 
Introduction 
Pityriasis lichenoides (PL), an uncommon dermatitis, previously included in the 
parapsoriasis group, may appear in two clinical forms: the acute variant also known as 
pityriasis lichenoides et varioliformis acuta (PLEVA); and the chronic variant or 
pityriasis lichenoides chronica (PLC) [1]. 
The etiology of PLEVA remains unknown. Several hypotheses have been proposed to 
explain this dermatitis: an inflammatory reaction triggered by infectious agents, an  
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inflammatory response secondary to T-cell dyscrasia, or an immune complex-mediated 
hypersensitivity [2]. 
Case Report 
A 63-year-old previously healthy man gradually developed, over 2 weeks, a widespread 
polymorphous and generalized eruption with papular and ulcerohemorrhagic skin lesions associated 
in the last days with fever, malaise, and myalgia that prompted his admittance to our department. His 
personal and family histories were non-contributory. He denied taking any medications and there was 
no apparent episode of any infection before the onset of the eruption.  
Physical skin examination revealed confluent erythematous and/or purpuric macules, papules, 
plaques with peripheral scaling, vesicopustules, and ulceronecrotic lesions with hemorrhagic crusts 
(fig. 1). Lesions in different evolutionary stages varying in size from 5 to 20 mm were observed on the 
trunk and extremities, including palms and soles, and were particularly exuberant in the flexural, 
neck, and genital area (fig. 2). Face and mucous membranes were spared. The patient had a slight 
fever (38°C) and reported malaise and myalgia only on the first day of hospitalization. Pruritus was 
modest. No adenopathies or other objective signs were detected during the physical examination. 
Laboratory findings included full blood cell count with differential, liver, and renal studies, serum 
protein electrophoresis, immunoglobulins, C3, C4, and antinuclear antibodies; serology for hepatitis B 
virus, hepatitis C virus, HIV, Epstein-Barr virus, cytomegalovirus, herpes simplex virus and 
Toxoplasmosis as well as Treponema pallidum were normal or negative. Direct immunofluorescence 
for HSV or VZV and viral cultures from the vesicles taken on the day of admission as well as bacterial 
skin cultures were negative. 
Histopathology showed mild acanthosis, vacuolization of the basal layer with necrotic 
keratinocytes and exocytosis of red blood cells and lymphocytes, and a dermal perivascular and 
periadnexal lymphocytic infiltrate with no atypia (fig. 3). On immunohistochemistry staining, 
infiltrating cells were mostly positive for CD8 and negative for CD4 and CD30, therefore indicating the 
diagnosis of PLEVA with a predominance of CD8 cells without CD30 cells, in which case 
lymphomatoid papulosis was less likely. 
Oral erythromycin (1 g per day), topical corticosteroids, and antihistamines were prescribed, but 
because of an insufficient clinical response after 2 weeks, oral methylprednisolone (32 mg/day) was 
added. Erythromycin was given for 3 months, and the systemic steroids were tapered gradually over 5 
months, with residual macular pigmented lesions still persisting at the end of this treatment. Regular 
clinical and laboratorial follow-up for the next 2 years showed no recurrence of skin lesions or any 
other systemic alteration. 
Discussion 
It is generally accepted that PLEVA and PLC represent two ends of a continuous 
spectrum, and therefore it is not uncommon to observe both acute and chronic lesions 
in the same patient, as well as lesions at intermediate stages between PLEVA and PLC 
[3]. 
PLEVA is characterized by erythematous macules that quickly evolve into papules 
with a fine micaceous scale. As the scale thickens, it often becomes free at the periphery 
but remains attached centrally. The papule often has a central punctum that becomes 
vesiculopustular, undergoes hemorrhagic necrosis, and becomes ulcerated, with 
overlying red-brown crusts. Varioliform scars and postinflammatory hyper- and 
hypopigmentation may result. Symptoms include burning and pruritus. PLEVA most 
often occurs on the trunk, extremities, and flexural areas, but diffuse and generalized  
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patterns may also occur. The eruption is polymorphous, as lesions exist in all stages of 
development, and successive crops of lesions can last indefinitely, from a few weeks to 
months or years [4]. 
The differential diagnosis for PLEVA includes lymphomatoid papulosis (the 
condition most commonly mistaken for PLEVA), arthropod bite reactions, varicella, 
Gianotti-Crosti syndrome, erythema multiforme, pityriasis rosea, guttate psoriasis, 
vasculitis, and secondary syphilis [1]. 
The relationship of pityriasis lichenoides to lymphomatoid papulosis remains 
controversial. Differentiation between these two conditions is, however, important 
because patients with lymphomatoid papulosis, unlike those with pityriasis 
lichenoides, may develop systemic lymphoma [5]. The presence of large CD30+ atypical 
lymphoid cells is the hallmark of lymphomatoid papulosis [6]. Other differences include 
the presence of large, atypical, non-lymphoid cells that may resemble Reed-Sternberg 
cells, many neutrophils, few lymphocytes, few or no necrotic keratinocytes, and little or 
no vacuolar degeneration of the basal layer, observed in lymphomatoid papulosis as 
opposed to PLEVA [5]. Clinically, the papules of lymphomatoid papulosis may develop 
into nodules, tumors, and large plaques (unlike PLEVA). The cutaneous eruption tends 
to last much longer than that of PLEVA, sometimes even for years [1]. 
Clinical management of PL is difficult due to its uncertain etiology. Since the disease 
tends towards self-resolution, evaluation of treatments without adequate controls 
cannot result in useful recommendations. Case reports suggest the use of multiple oral 
medications including tetracycline [7], erythromycin [8], methotrexate, calciferol, 
chinoline and acridine derivates, cyclosporine, intravenous gamma globulin, and 
retinoids [1]. Systemic corticosteroids may have a role in severe cases of PLEVA. 
Topical corticosteroids and antihistamines are helpful in symptomatic cases, but they 
do not alter the course of the disease. Recently, good responses with topical tacrolimus 
treatment were reported [9]. Current knowledge about the efficacy of phototherapy for 
PL is limited and is mostly based on anecdotal reports and small-scale studies [10]. 
Despite a lack of randomized controlled trials, oral tetracycline and erythromycin 
have been prescribed most often in case series. 
In conclusion, the authors want to remind of this rare entity which may present 
difficulties in diagnosis and therapy. Exocytosis of T cells, with a CD8+/CD30– 
phenotype, favors the diagnosis of PLEVA and excludes lymphomatoid papulosis. 
Macrolid and steroid was effective in this patient, even though one cannot exclude the 
possibility of a spontaneous resolution. 
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Fig. 1. Ulceronecrotic lesions with hemorrhagic crusts varying from 5 to 20 mm in diameter. 
 
 
 
Fig. 2. Polymorphous clinical appearance of early lesions. 
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Fig. 3. Histopathology showing mild acanthosis, vacuolization of the basal layer with necrotic 
keratinocytes and exocytosis of red blood cells and lymphocytes. In the dermis, a lymphocytic 
perivascular and periadnexal inflammatory infiltrate can be observed. The infiltrating cells showed 
no atypia. HE, ×100. 
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